BioMS Medical recognized at Scrip A...( Toronto Stock Exchange Symbol: MS ....)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
BioMS Medical recognized at Scrip Awards 2008
Date:12/11/2008
Toronto Stock Exchange Symbol: MS
EDMONTON, Dec. 11 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the Company was the recipient of the "Licensing Deal of the Year Award" at the 4th Annual Scrip Awards held in London, U.K. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company (Lilly) exclusive worldwide rights to dirucotide, for the treatment of MS, in exchange for an US$87 million upfront payment, potential development and sales milestones up to US$410 million and escalating royalties on sales.
"We are honored to receive this award which recognizes the significance of the alliance between BioMS and our partner Lilly," said Kevin Giese, President and CEO of BioMS Medical. "This partnership demonstrates a mutual commitment focused on developing an effective therapeutic option for patients with secondary progressive MS, a debilitating disease of global proportion for which there are limited treatment options."
About The Scrip Awards 2008
---------------------------
The Scrip Awards, hosted by Informa Healthcare - one of the world's leading medical and scientific publishers - brings together hundreds of senior-level industry experts at one of the industry's most prestigious and hotly contested awards ceremony, to highlight the achievements of pharmaceutical companies throughout the year. For further information visit http://scripawards.com.
About BioMS Medical Corp.
-------------------------
BioMS Medical is a Canadian biotech company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivot
'/>"/>
| SOURCE BioMS Medical Corp. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
(Date:12/2/2009)...swire/ -- S*BIO Pte Ltd today announced data prese... at The American Society of Hematology 51st Annual... will be presented on the clinical results from th...g its safety, tolerability and pharmacokinetic/pha...g from 100 to 600 mg. These doses were administere...
(Date:12/2/2009).../PRNewswire-Asia/ -- Simcere Pharmaceutical Group,...ding pharmaceutical company,specializing in the de...,generic and proprietary pharmaceuticals in China,...ncluded in China,s National Drug Reimbursement Lis...f Human Resources and Social,Security on November ...
(Date:12/2/2009)...swire-Asia/ -- The world is going through,extraord...y is part of many,businesses and industries. It tu...ly immune to the economic downturn, because illnes...idst of the difficult times this year, the pharmac... R&D center in Shanghai, the largest of,its ki...
(Date:12/2/2009)...wire/ -- According to the National Institute of He...sed with diabetes already have some stage of diabe...the retina caused by leaky blood vessels, is a maj...is one of the most feared diabetic complications. ...had diabetes for 10 years or more will experience ...
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4[0] S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders[0] Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List[0] Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit[0] Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy
...11 Schering-Plough Corporation (NYSE: SGP ) wil...y, May 18, 2009, in Chicago at 7:30 a.m. (CDT) (8:...meeting will be available to all interested partie...h.com . , , At the Annual Meeting, Fred Hassan, ...he company,s performance and progress. , , The p...
...VER, May 11 /PRNewswire-FirstCall/ - OncoGenex Pha...ay that final survival data from a randomized Phas...ocetaxel versus docetaxel alone as first-line chem...sistant prostate cancer will be featured in an ora... Oncology (ASCO) Annual Meeting. In addition, Phas...
...n now calibrate high-power laser systems, such as ...ickly and easily thanks to a novel nanotube-coated...l Institute of Standards and Technology (NIST). ,...Force base last week, will be used to measure the ...ight focused from a 10 kW laser is more than a mil...
Other Biology Technology:Schering-Plough Schedules Webcast For Annual Meeting of Shareholders 2OncoGenex Pharmaceuticals' Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting 2OncoGenex Pharmaceuticals' Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting 3New nanotube coating enables novel laser power meter 2(Date:12/2/2009)...witch, before the thought telling it to flex can r...ed an ion channelmust open in the surface of each ...s that spur the cell to action. New research* at t...(NIST) has allowed scientists to observe ion chann..., potentially offering insights for future drug de...
(Date:12/2/2009)...of Salamanca and another from Yale University have...behaviour of Acanthodactylus beershebensis , a li...t. According to the study, these reptiles move les... are under pressure from predators. , Many theor... now there had been very few experimental trials a...
(Date:12/1/2009)...fferent feeding strategies. A large proportion of...are generalist predators feeding on other small an...er, are "herbivorous". This is not to say that th...s consist of plant-derived matter. For example, so...ttract ants, called extra-floral nectar; others fe...
Breaking Biology News(10 mins):Nervy research: Researchers take initial look at ion channels in a model system 2Lizards change their diet to avoid predators 2Bacterial gut symbionts are tightly linked with the evolution of herbivory in ants 2Health Club Media Network Adds New York Health 26 Racquet Club 53326 1Health Club Media Network Adds New York Health 26 Racquet Club 53326 2Cutting Edge iPhone 28TM 29 iPod 28R 29 Touch Apps Improve Quality of Life for Those With Celiac Coeliac 26 Food Allergies 53324 1Cutting Edge iPhone 28TM 29 iPod 28R 29 Touch Apps Improve Quality of Life for Those With Celiac Coeliac 26 Food Allergies 53324 2United Therapeutics Corporation Reports Second Quarter 2009 Financial Results 53323 1United Therapeutics Corporation Reports Second Quarter 2009 Financial Results 53323 2United Therapeutics Corporation Reports Second Quarter 2009 Financial Results 53323 3United Therapeutics Corporation Reports Second Quarter 2009 Financial Results 53323 4United Therapeutics Corporation Reports Second Quarter 2009 Financial Results 53323 5United Therapeutics Corporation Reports Second Quarter 2009 Financial Results 53323 6United Therapeutics Corporation Reports Second Quarter 2009 Financial Results 53323 7United Therapeutics Corporation Reports Second Quarter 2009 Financial Results 53323 8United Therapeutics Corporation Reports Second Quarter 2009 Financial Results 53323 9...h scientists contributed by invitation to an inter...de, president of Senegal, to identify strategies f...est Africa. Last year, locusts stripped fields of ...s, causing severe income and food supply loss. , ...SAID-funded Integrated Pest Management Collaborati...
...s can leave its patients miserable and debilitated...ors. Infants affected by the disease face possible.... , The disease frustrates doctors because there,...le gene was identified more than a decade ago. Cur...affects more people than cystic fibrosis, heredita...
...ale, in collaboration with NIH researchers, have i... by the immune system for detection of parasitic i...re vaccines to combat these infections. , Publishe...udy provides insight into understanding how infect... problem of great scientific and clinical importan...
Other Biology News:Scientists discuss improved biopesticides for locust control in West Africa 2Potential treatments for neurofibromatosis 2Potential treatments for neurofibromatosis 3Yale researchers identify molecule for detecting parasitic infection in humans 2Goat Anti-Human EML1 (K-16) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
BCASMC (B350-05) from European Collection of Cell Cultures (ECACC)
BAOSMC (B354-05) from European Collection of Cell Cultures (ECACC)
Adaptor for ABI 3700 (AB-0800) from ABgene
Biology Products:| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |